Pfizer Inc. $PFE Shares Purchased by CW Advisors LLC

Key Points

• CW Advisors LLC has increased its stake in Pfizer Inc. by 55.8% during the first quarter, amounting to 527,799 shares valued at approximately $13.45 million.
• Pfizer reported $0.78 earnings per share (EPS) for the last quarter, surpassing the consensus estimate of $0.58, with a revenue of $14.65 billion.
• Pfizer will pay a quarterly dividend of $0.43 per share on September 2nd, offering a yield of 6.7%, while its dividend payout ratio stands at 91.49%.

CW Advisors LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 55.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 527,799 shares of the biopharmaceutical company's stock after acquiring an additional 189,057 shares during the period. CW Advisors LLC's holdings in Pfizer were worth $13,453,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Clarity Asset Management Inc. purchased a new position in Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the first quarter worth approximately $27,000. North Capital Inc. purchased a new position in Pfizer during the first quarter worth approximately $28,000. Finally, Bayforest Capital Ltd purchased a new position in Pfizer during the first quarter worth approximately $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE:PFE opened at $25.7060 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market cap of $146.15 billion, a PE ratio of 13.67, a P/E/G ratio of 0.90 and a beta of 0.52. The stock has a 50 day moving average price of $24.68 and a 200 day moving average price of $24.42.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer's dividend payout ratio (DPR) is 91.49%.

Analyst Upgrades and Downgrades

PFE has been the topic of several research reports. Jefferies Financial Group raised their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. The Goldman Sachs Group raised their target price on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, Bank of America raised their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.